(Total Views: 998)
Posted On: 09/06/2019 7:25:16 PM
Post# of 416
NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Planning Nationwide Rollout of Pain-Management Device
Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, plans to have its innovative pain-management device available in all 50 states by 2020. An article discussing the company reads, “Technological advancements in the field will also contribute to the market’s growth by enabling the development of more effective devices. There are multiple types of pain-management devices. The market is currently dominated by neurostimulation devices, which accounted for over 50% of the sector’s revenue generated in 2018. This segment is anticipated to maintain its industry dominance over the forecast period. . . . Recently, Endonovo announced the rollout of SofPulse(R) in hospital and medical centers across the U.S. The company plans to be in the evaluation stage with 600 hospitals within the next 18 months. ‘We believe, based on numerous meetings with doctors and hospital administrators, the level of acceptance of our SofPulse(R) device supports our plans to be in hospitals throughout all 50 states by 2020,’ Endonovo CEO Alan Collier said in a news release.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, plans to have its innovative pain-management device available in all 50 states by 2020. An article discussing the company reads, “Technological advancements in the field will also contribute to the market’s growth by enabling the development of more effective devices. There are multiple types of pain-management devices. The market is currently dominated by neurostimulation devices, which accounted for over 50% of the sector’s revenue generated in 2018. This segment is anticipated to maintain its industry dominance over the forecast period. . . . Recently, Endonovo announced the rollout of SofPulse(R) in hospital and medical centers across the U.S. The company plans to be in the evaluation stage with 600 hospitals within the next 18 months. ‘We believe, based on numerous meetings with doctors and hospital administrators, the level of acceptance of our SofPulse(R) device supports our plans to be in hospitals throughout all 50 states by 2020,’ Endonovo CEO Alan Collier said in a news release.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
